Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts

PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%–50% of patients will eventually have relapsed or refractory disease, whose prognosis i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Jun Ho, Jeong, Seong Hyun, Kim, Seok Jin, Yoon, Dok Hyun, Kang, Hye Jin, Koh, Youngil, Kim, Jin Seok, Lee, Won-Sik, Yang, Deok-Hwan, Do, Young Rok, Kim, Min Kyoung, Yoo, Kwai Han, Choi, Yoon Seok, Yun, Whan Jung, Park, Yong, Jo, Jae-Cheol, Eom, Hyeon-Seok, Kwak, Jae-Yong, Shin, Ho-Jin, Park, Byeong Bae, Yi, Seong Yoon, Kwon, Ji-Hyun, Oh, Sung Yong, Kim, Hyo Jung, Sohn, Byeong Seok, Won, Jong Ho, Hong, Dae-Sik, Lee, Ho-Sup, Lee, Gyeong-Won, Suh, Cheolwon, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873324/
https://www.ncbi.nlm.nih.gov/pubmed/35468269
http://dx.doi.org/10.4143/crt.2022.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873324/
https://www.ncbi.nlm.nih.gov/pubmed/35468269
http://dx.doi.org/10.4143/crt.2022.008

Ejemplares similares